Clinical trials: Lines Skin
Breast Cancer
Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer
This is a prospective, single arm phase II study to evaluate the efficacy and safety of fulvestrant as a maintenance hormone therapy after first-line chemotherapy for postmenopausal HR positive advanced breast cancer.
- Trial name
- FANCY (NCT02000193)
- Testing
- fulvestrant
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer
Primary Objectives: 1. To validate the prognostic significance of circulating tumor cells (CTCs) in patients with newly diagnosed metastatic breast cancer (MBC). 2.
- Trial name
- NCT00493350
- Testing
- Blood Sample
- Where
- United States
- Volunteers
- 660 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Immune Thrombocytopenia (ITP)
rhTPO Dose Escalation vs Eltrombopag Switch in ITP
This study is a prospective, multicenter, randomized controlled study, planning to enroll 110 ITP patients who failed to respond to conventional-dose rhTPO (300 IU/kg/d) after 14 days of treatment (PLT < 30×10⁹/L).
- Trial name
- NCT07476846
- Testing
- Recombinant Human Thrombopoietin（rhTPO）, Eltrombopag PfOS
- Volunteers
- 112 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Arthritis, Rheumatoid
Remicade Safety Line (Study P03236)(COMPLETED)
The goal of this study is to implement instruments that would increase the treating physician's awareness of the necessary tuberculosis screening when starting a new patient on infliximab (Remicade) therapy who has not reacted…
- Trial name
- NCT00748826
- Testing
- Infliximab
- Volunteers
- 576 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Metastases
DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer
The purpose of this trial is to study DPPE combined with epirubicin and cyclophosphamide in patients with metastatic and/or recurrent breast cancer who may have received previous hormone treatment but have not had exposure to…
- Trial name
- NCT00099281
- Testing
- YMB 1002
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- YM BioSciences
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Atopic Dermatitis
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
This is a low-intervention phase IV trial. The main objective is to optimize the treatment of patients with moderate-severe atopic dermatitis that require systemic treatment after failure, intolerance or contraindication to…
- Trial name
- NCT06366932
- Testing
- Second-line systemic treatment, Folllow-up of second-line systemic treatment already started
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Blood Stream Infections, Skin Diseases, Infectious
Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections
The purpose of the study is to determine if the overall central venous catheter related infection rate can be reduced by the application of Polysporin Triple Therapy ointment to the insertion site.
- Trial name
- ToPICL (NCT00990392)
- Testing
- Polysporin Triple Therapy ointment, Petroleum Jelly
- Where
- Canada
- Sponsor
- Fraser Health
Immune Thrombocytopenia
Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate
This is a study of two treatment pathways [Standard steroid treatment versus combined steroid and Mycophenolate (MMF)] for subjects with newly diagnosed Immune Thrombocytopenia (ITP).
- Trial name
- FLIGHT (NCT03156452)
- Testing
- Mycophenolate Mofetil, Prednisolone
- Where
- United Kingdom
- Volunteers
- 123 people
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Scleroderma, Localized, Morphea
Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
The Morphea in Adults and Children (MAC) cohort is the first registry for both children and adults with morphea (also known as localized scleroderma) in the country.
- Conditions
- Scleroderma, Localized, Morphea, Frontal Linear Scleroderma en Coup de Sabre, Scleroderma, Circumscribed
- Trial name
- MAC (NCT01808937)
- Testing
- Morphea
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Acne Vulgaris
Comedone Extraction and Oral Doxycycline In The First Line Treatment of Moderate Acne Vulgaris
The objective of the study was to evaluate the effectiveness of comedone extraction compared to oral antibiotics as the main therapy of moderate acne vulgaris (MAV); and to determine the expression of HIF-1 alpha by examining the…
- Trial name
- NCT04206631
- Testing
- Doxycycline Capsule, Comedone extraction
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Pulse Oximetry
Pulse Oximetry and Skin Pigmentation - Peds
The investigators' study aims to study how melanin index (mx) affects the deviation between SpO2 and SaO2, which becomes generally greater as hypoxia increases.
- Trial name
- NCT05185427
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Minnesota
Pompe Disease, Glycogen Storage Disease Type II
A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease
The purpose of this study is to see how molecules called pharmacological chaperones affect the cells of patients with Pompe disease.
- Trial name
- NCT00515398
- Testing
- Observation
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Amicus Therapeutics
High Risk HLA-A2+ Melanoma, Metastatic Disease
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
This study is based on the hypothesis that stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low…
- Trial name
- NCT01861938
- Testing
- Melanoma vaccine modified to express HLA A2/4-1BB ligand
- Sponsor
- Hadassah Medical Organization
Metastatic Breast Cancer, ER Positive Breast Cancer
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
This is a multi-center biomarkers study aiming to prospectively collect biological samples from patients with ER+ and HER2-negative metastatic breast cancer, who are candidate to first-line treatment with an aromatase inhibitor…
- Conditions
- Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- TIRESIAS (NCT04660435)
- Testing
- Thymidine kinase activity
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Sandro Pitigliani
Breast Cancer
A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer
To explore a reasonable and effective way to reduce the incidence of grade 3 or above diarrhea caused by pyrotinib
- Trial name
- NCT06362096
- Testing
- Trastuzumab+pyrotinib+taxene
- Volunteers
- 72 people
- Sponsor
- Huihua Xiong
Malignant Melanoma
Modified Vaccine for High Risk or Low Residual Melanoma Patients
This study is designed for patients who had malignant melanoma and, following tumor removal, are now free of disease, or have only very minor residual disease, and are at a very high risk of disease recurrence.
- Trial name
- NCT01898039
- Testing
- A2/4-1BBL melanoma vaccine, DNP sensititzation, Cyclophosphamide
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Primary Immunodeficiency, DOCK8
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Background: National Institutes of Health (NIH) researchers have been studying immune cells (white blood cells) to better understand how the human body s defense system works and adjusts or regulates itself, and how changes in…
- Conditions
- Primary Immunodeficiency, DOCK8, Virus Susceptibility
- Trial name
- NCT00895271
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteer, Sjogren's Syndrome
Characterization of Diseases With Salivary Gland Involvement
Background: Salivary glands in and around the mouth and throat make saliva. Salivary gland disorders can affect a person s quality of life.
- Conditions
- Healthy Volunteer, Sjogren's Syndrome, Salivary Gland Disease
- Trial name
- NCT02327884
- Where
- United States
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)